The genetics of gestational diabetes mellitus: Evidence for relationship with type 2 diabetes mellitus

Genetics in Medicine

Volumn 10, Issue 4, 2008, Pages 240-250

  Robitaille, Julie ^a   Grant, Althea M ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Association studies; Genetics; Gestational diabetes mellitus; Pregnancy; Type 2 diabetes

Indexed keywords

ADIPONECTIN; BETA 3 ADRENERGIC RECEPTOR; CALPAIN 10; GLUCOSE; GLUCOSE TRANSPORTER 1; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MANNOSE BINDING LECTIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM CHANNEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SOMATOMEDIN B; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR FOXC2; UNCOUPLING PROTEIN 2;

GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY DIABETES MELLITUS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 42149122068     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31816b8710     Document Type: Review

References (157)

1. American Diabetes Association. Gestational diabetes 2006 [internet communication]. 2006.
2. Phillips PJ, Jeffries B. Gestational diabetes-worth finding and actively treating. Aust Fam Physician 2006;35:701-703.
3. Lobner K, Knopff A, Baumgarten A, Mollenhauer U, et al. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes 2006;55:792-797.
4. Silverman BL, Rizzo TA, Cho NH, Metzger BE. Long-term effects of the intrauterine environment. The Northwestern university diabetes in pregnancy center. Diabetes Care 1998;21(suppl 2):B142-B149.
5. Permutt MA, Wasson J, Cox N. Genetic epidemiology of diabetes. J Clin Invest 2005;115:1431-1439.
6. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest 2005;115:485-491.
7. Buchanan TA. Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 2001;86:989-993.
8. Williams MA, Qiu C, Dempsey JC, Luthy DA. Familial aggregation of type 2 diabetes and chronic hypertension in women with gestational diabetes mellitus. J Reprod Med 2003;48:955-962.
9. Martin AO, Simpson JL, Ober C, Freinkel N. Frequency of diabetes mellitus in mothers of probands with gestational diabetes: possible maternal influence on the predisposition to gestational diabetes. Am J Obstet Gynecol 1985;151:471-475.
10. Harder T, Franke K, Kohlhoff R, Plagemann A. Maternal and paternal family history of diabetes in women with gestational diabetes or insulin-dependent diabetes mellitus type I. Gynecol Obstet Invest 2001;51:160-164.
11. Barroso I. Genetics of Type 2 diabetes. Diabet Med 2005;22:517-535.
12. Froguel P, Velho G. Genetic determinants of type 2 diabetes. Recent Prog Horm Res 2001;56:91-105.
13. Malecki MT. Genetics of type 2 diabetes mellitus. Diabetes Res Clin Pract 2005;68(suppl 1):S10-S21.
14. Shaat N, Groop L. Genetics of gestational diabetes mellitus. Curr Med Chem 2007;14:569-583.
15. Gloyn AL, Siddiqui J, Ellard S. Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 2006;27:220-231.
16. Hart LM, Stolk RP, Dekker JM, Nijpels G, et al. Prevalence of variants in candidate genes for type 2 diabetes mellitus in The Netherlands: the Rotterdam study and the Hoorn study. J Clin Endocrinol Metab 1999;84:1002-1006.
17. Hart LM, Dekker JM, van Haeften TW, Ruige JB, et al. Reduced second phase insulin secretion in carriers of a sulphonylurea receptor gene variant associating with Type II diabetes mellitus. Diabetologia 2000;43:515-519.
18. Inoue H, Ferrer J, Welling CM, Elbein SC, et al. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes 1996;45:825-831.
19. Rissanen J, Markkanen A, Karkkainen P, Pihlajamaki J, et al. Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and type 2 diabetes but not with altered secretion of insulin. Diabetes Care 2000;23:70-73.
20. Goksel DL, Fischbach K, Duggirala R, Mitchell BD, et al. Variant in sulfonylurea receptor-1 gene is associated with high insulin concentrations in non-diabetic Mexican Americans: SUR-1 gene variant and hyperinsulinemia. Hum Genet 1998;103:280-285.
21. Schwanstecher C, Meyer U, Schwanstecher M. K(IR)6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic beta-cell ATP-sensitive K(+) channels. Diabetes 2002;51:875-879.
22. van Dam RM, Hoebee B, Seidell JC, Schaap MM, et al. Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses. Diabet Med 2005;22:590-598.
23. Hani EH, Boutin P, Durand E, Inoue H, et al. Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia 1998;41:1511-1515.
24. Shaat N, Ekelund M, Lernmark A, Ivarsson S, et al. Association of the E23K polymorphism in the KCNJ11 gene with gestational diabetes mellitus. Diabetologia 2005;48:2544-2551.
25. Zhang CY, Baffy G, Perret P, Krauss S, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 2001;105:745-755.
26. Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, et al. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001;28:178-183.
27. Wang H, Chu WS, Lu T, Hasstedt SJ, et al. Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol Endocrinol Metab 2004;286:E1-E7.
28. Maassen JA, Jahangir Tafrechi RS, Janssen GM, Raap AK, et al. New insights in the molecular pathogenesis of the maternally inherited diabetes and deafness syndrome. Endocrinol Metab Clin North Am 2006;35:385-396, x-xi.
29. Guo LJ, Oshida Y, Fuku N, Takeyasu T, et al. Mitochondrial genome polymorphisms associated with type-2 diabetes or obesity. Mitochondrion 2005;5:15-33.
30. Tang DL, Zhou X, Li X, Zhao L, et al. Variation of mitochondrial gene and the association with type 2 diabetes mellitus in a Chinese population. Diabetes Res Clin Pract 2006;73:77-82.
31. Yu P, Yu DM, Liu DM, Wang K, et al. Relationship between mutations of mitochondrial DNA ND1 gene and type 2 diabetes. Chin Med J (Engl) 2004;117:985-989.
32. Chen Y, Liao WX, Roy AC, Loganath A, et al. Mitochondrial gene mutations in gestational diabetes mellitus. Diabetes Res Clin Pract 2000;48:29-35.
33. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-323.
34. Palmer ND, Lehtinen AB, Langefeld CD, Campbell JK, et al. Association of TCF7L2 gene polymorphisms with reduced acute insulin response in Hispanic Americans. J Clin Endocrinol Metab 2008;93:304-309
35. Loos RJ, Franks PW, Francis RW, Barroso I, et al. TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 2007;56:1943-1947.
36. Munoz J, Lok KH, Gower BA, Fernandez JR, et al. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes 2006;55:3630-3634.
37. Shaat N, Lernmark A, Karlsson E, Ivarsson S, et al. A variant in the transcription factor 7-like 2 (TCF7L2) gene is associated with an increased risk of gestational diabetes mellitus. Diabetologia 2007;50:972-979.
38. Watanabe RM, Allayee H, Xiang AH, Trigo E, et al. Transcription factor 7-like 2 (TCF7L2) is associated with gestational diabetes mellitus and interacts with adiposity to alter insulin secretion in Mexican Americans. Diabetes 2007;56:1481-1485.
39. Bell GI, Selby MJ, Rutter WJ. The highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences. Nature 1982;295:31-35.
40. Kennedy GC, German MS, Rutter WJ. The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. Nat Genet 1995;9:293-298.
41. Lucassen AM, Screaton GR, Julier C, Elliott TJ, et al. Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. Hum Mol Genet 1995;4:501-506.
42. Bennett ST, Todd JA. Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet 1996;30:343-370.
43. Meigs JB, Dupuis J, Herbert AG, Liu C, et al. The insulin gene variable number tandem repeat and risk of type 2 diabetes in a population-based sample of families and unrelated men and women. J Clin Endocrinol Metab 2005;90:1137-1143.
44. Hansen SK, Gjesing AP, Rasmussen SK, Glumer C, et al. Large-scale studies of the HphI insulin gene variable-number-of-tandem-repeats polymorphism in relation to Type 2 diabetes mellitus and insulin release. Diabetologia 2004;47:1079-1087.
45. Lindsay RS, Hanson RL, Wiedrich C, Knowler WC, et al. The insulin gene variable number tandem repeat class I/III polymorphism is in linkage disequilibrium with birth weight but not Type 2 diabetes in the Pima population. Diabetes 2003;52:187-193.
46. Shaat N, Ekelund M, Lernmark A, Ivarsson S, et al. Genotypic and phenotypic differences between Arabian and Scandinavian women with gestational diabetes mellitus. Diabetologia 2004;47:878-884.
47. Litou H, Anastasiou E, Thalassinou L, Sarika HL, et al. Increased prevalence of VNTR III of the insulin gene in women with gestational diabetes mellitus (GDM). Diabetes Res Clin Pract 2007;76:223-228.
48. Taylor SI, Accili D, Cama A, Imano E, et al. Unusual forms of insulin resistance. Annu Rev Med 1991;42:373-379.
49. Morgan R, Bishop A, Owens DR, Luzio SD, et al. Allelic variants at insulin-receptor and insulin gene loci and susceptibility to NIDDM in Welsh population. Diabetes 1990;39:1479-1484.
50. Flores-Martinez SE, Islas-Andrade S, Horro-Lazo MV, Revilla MC, et al. DNA polymorphism analysis of candidate genes for type 2 diabetes mellitus in a Mexican ethnic group. Ann Genet 2004;47:339-348.
51. Lepretre F, Vionnet N, Budhan S, Dina C, et al. Genetic studies of polymorphisms in ten non-insulin-dependent diabetes mellitus candidate genes in Tamil Indians from Pondicherry. Diabetes Metab 1998;24:244-250.
52. Magre J, Goldfine AB, Warram JH, Krolewski AS, et al. Analysis of the insulin receptor gene in noninsulin-dependent diabetes mellitus by denaturing gradient gel blots: a clinical research center study. J Clin Endocrinol Metab 1995;80:1882-1887.
53. Ober C, Xiang KS, Thisted RA, Indovina KA, et al. Increased risk for gestational diabetes mellitus associated with insulin receptor and insulin-like growth factor II restriction fragment length polymorphisms. Genet Epidemiol 1989;6:559-569.
54. Bonner-Weir S. Life and death of the pancreatic beta cells. Trends Endocrinol Metab 2000;11:375-378.
55. Kido Y, Nakae J, Hribal ML, Xuan S, et al. Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance. J Biol Chem 2002;277:36740-36747.
56. Da Costa TH, Williamson DH, Ward A, Bates P, et al. High plasma insulin-like growth factor-II and low lipid content in transgenic mice: measurements of lipid metabolism. J Endocrinol 1994;143:433-439.
57. Rogler CE, Yang D, Rossetti L, Donohoe J, et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994;269:13779-13784.
58. Heald AH, Karvestedt L, Anderson SG, McLaughlin J, et al. Low insulin-like growth factor-II levels predict weight gain in normal weight subjects with type 2 diabetes. Am J Med 2006;119:167-115.
59. Villuendas G, Botella-Carretero JI, Lopez-Bermejo A, Gubern C, et al. The ACAA-insertion/deletion polymorphism at the 3′ UTR of the IGF-II receptor gene is associated with type 2 diabetes and surrogate markers of insulin resistance. Eur J Endocrinol 2006;155:331-336.
60. Sun XJ, Rothenberg P, Kahn CR, Backer JM, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991;352:73-77.
61. McGettrick AJ, Feener EP, Kahn CR. Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation. J Biol Chem 2005;280:6441-6446.
62. Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, et al. Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies. Diabetologia 2003;46:990-995.
63. Fallucca F, Dalfra MG, Sciullo E, Masin M, et al. Polymorphisms of insulin receptor substrate 1 and beta3-adrenergic receptor genes in gestational diabetes and normal pregnancy. Metabolism 2006;55:1451-1456.
64. Tok EC, Ertunc D, Bilgin O, Erdal EM, et al. Association of insulin receptor substrate-1 G972R variant with baseline characteristics of the patients with gestational diabetes mellitus. Am J Obstet Gynecol 2006;194:868-872.
65. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-435.
66. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
67. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
68. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006;116:615-622.
69. Esterbauer H, Oberkofler H, Linnemayr V, Iglseder B, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with obesity indices in middle-aged women. Diabetes 2002;51:1281-1286.
70. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 2004;47:2176-2184.
71. Chen S, Yan W, Huang J, Yang W, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha polymorphism is not associated with essential hypertension and type 2 diabetes mellitus in Chinese population. Hypertens Res 2004;27:813-820.
72. Ek J, Andersen G, Urhammer SA, Gaede PH, et al. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 2001;44:2220-2226.
73. Hara K, Tobe K, Okada T, Kadowaki H, et al. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia 2002;45:740-743.
74. Lacquemant C, Chikri M, Boutin P, Samson C, et al. No association between the G482S polymorphism of the proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene and Type II diabetes in French Caucasians. Diabetologia 2002;45:602-603.
75. Vimaleswaran KS, Radha V, Ghosh S, Majumder PP, et al. Peroxisome proliferator-activated receptor-gamma co-activator-1alpha (PGC-1alpha) gene polymorphisms and their relationship to Type 2 diabetes in Asian Indians. Diabet Med 2005;22:1516-1521.
76. Leipold H, Knoefler M, Gruber C, Huber A, et al. Peroxisome proliferator-activated receptor gamma coactivator-1alpha gene variations are not associated with gestational diabetes mellitus. J Soc Gynecol Investig 2006;13:104-107.
77. Krief S, Lonnqvist F, Raimbault S, Baude B, et al. Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest 1993;91:344-349.
78. Lonnqvist F, Thome A, Nilsell K, Hoffstedt J, et al. A pathogenic role of visceral fat beta 3-adrenoceptors in obesity. J Clin Invest 1995;95:1109-1116.
79. Clement K, Vaisse C, Manning BS, Basdevant A, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 1995;333:352-354.
80. Walston J, Silver K, Bogardus C, Knowler WC, et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 1995;333:343-347.
81. Candelore MR, Deng L, Tota LM, Kelly LJ, et al. Pharmacological characterization of a recently described human beta 3-adrenergic receptor mutant. Endocrinology 1996;137:2638-2641.
82. Pietri-Rouxel F, St John MB, Gros J, Strosberg AD. The biochemical effect of the naturally occurring Trp64->Arg mutation on human beta3-adrenoceptor activity. Eur J Biochem 1997;247:1174-1179.
83. Weng J, Ekelund M, Lehto M, Li H, et al. Screening for MODY mutations, GAD antibodies, and type 1 diabetes-associated HLA genotypes in women with gestational diabetes mellitus. Diabetes Care 2002;25:68-71.
84. Strosberg AD. Association of beta 3-adrenoceptor polymorphism with obesity and diabetes: current status. Trends Pharmacol Sci 1997;18:449-454.
85. Fujisawa T, Ikegami H, Yamato E, Takekawa K, et al. Association of Trp64Arg mutation of the beta3-adrenergic-receptor with NIDDM and body weight gain. Diabetologia 1996;39:349-352.
86. Festa A, Krugluger W, Shnawa N, Hopmeier P, et al. Trp64Arg polymorphism of the beta3-adrenergic receptor gene in pregnancy: association with mild gestational diabetes mellitus. J Clin Endocrinol Metab 1999;84:1695-1699.
87. Alevizaki M, Thalassinou L, Grigorakis SI, Philippou G, et al. Study of the Trp64Arg polymorphism of the beta3-adrenergic receptor in Greek women with gestational diabetes. Diabetes Care 2000;23:1079-1083.
88. Tsai PJ, Ho SC, Tsai LP, Lee YH, et al. Lack of relationship between beta3-adrenergic receptor gene polymorphism and gestational diabetes mellitus in a Taiwanese population. Metabolism 2004;53:1136-1139.
89. Mueckler M, Caruso C, Baldwin SA, Panico M, et al. Sequence and structure of a human glucose transporter. Science 1985;229:941-945.
90. Kumagai AK. Glucose transport in brain and retina: implications in the management and complications of diabetes. Diabetes Metab Res Rev 1999;15:261-273.
91. Li SR, Baroni MG, Oelbaum RS, Stock J, et al. Association of genetic variant of the glucose transporter with non-insulin-dependent diabetes mellitus. Lancet 1988;2:368-370.
92. Baroni MG, Oelbaum RS, Pozzilli P, Stocks J, et al. Polymorphisms at the GLUT1 (HepG2) and GLUT4 (muscle/adipocyte) glucose transporter genes and non-insulin-dependent diabetes mellitus (NIDDM). Hum Genet 1992;88:557-561.
93. Tao T, Tanizawa Y, Matsutani A, Matsubara A, et al. HepG2/erythrocyte glucose transporter (GLUT1) gene in NIDDM: a population association study and molecular scanning in Japanese subjects. Diabetologia 1995;38:942-947.
94. Pontiroli AE, Capra F, Veglia F, Ferrari M, et al. Genetic contribution of polymorphism of the GLUT1 and GLUT4 genes to the susceptibility to type 2 (non-insulin-dependent) diabetes mellitus in different populations. Acta Diabetol 1996;33:193-197.
95. Cox NJ, Xiang KS, Bell GI, Karam JH. Glucose transporter gene and non-insulin-dependent diabetes. Lancet 1988;2:793-794.
96. Alcolado JC, Baroni MG. Restriction fragment length polymorphisms at the GLUT4 and GLUT1 gene loci in type 2 diabetes. Diabet Med 1992;9:58-60.
97. Gutierrez C, Vendrell J, Pastor R, Broch M, et al. GLUT1 gene polymorphism in non-insulin-dependent diabetes mellitus: genetic susceptibility relationship with cardiovascular risk factors and microangiopathic complications in a Mediterranean population. Diabetes Res Clin Pract 1998;41:113-120.
98. Gibson F, Froguel P. Genetics of the APM1 locus and its contribution to type 2 diabetes susceptibility in French Caucasians. Diabetes 2004;53:2977-2983.
99. Gu HF, Abulaiti A, Ostenson CG, Humphreys K, et al. Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians. Diabetes 2004;53(suppl 1):S31-S35.
100. Hara K, Boutin P, Mori Y, Tobe K, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002;51:536-540.
101. Populaire C, Mori Y, Dina C, Vasseur F, et al. Does the -11377 promoter variant of APM1 gene contribute to the genetic risk for Type 2 diabetes mellitus in Japanese families? Diabetologia 2003;46:443-445.
102. Schwarz PE, Towers GW, Fischer S, Govindarajalu S, et al. Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter. Diabetes Care 2006;29:1645-1650.
103. Schwarz PE, Govindarajalu S, Towers W, Schwanebeck U, et al. Haplotypes in the promoter region of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population. Horm Metab Res 2006;38:447-451.
104. Ukkola O, Santaniemi M, Rankinen T, Leon AS, et al. Adiponectin polymorphisms, adiposity and insulin metabolism: HERITAGE family study and Oulu diabetic study. Ann Med 2005;37:141-150.
105. Vasseur F, Helbecque N, Dina C, Lobbens S, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 2002;11:2607-2614.
106. Zacharova J, Chiasson JL, Laakso M. The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOPNIDDM trial. Diabetes 2005;54:893-899.
107. Ategbo JM, Grissa O, Yessoufou A, Hichami A, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab. 2006l;91:4137-4143.
108. Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, et al. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 2005;90:3983-3988.
109. Kinalski M, Telejko B, Kuzmicki M, Kretowski A, et al. Tumor necrosis factor alpha system and plasma adiponectin concentration in women with gestational diabetes. Horm Metab Res 2005;37:450-454.
110. Ranheim T, Haugen F, Staff AC, Braekke K, et al. Adiponectin is reduced in gestational diabetes mellitus in normal weight women. Acta Obstet Gynecol Scand 2004;83:341-347.
111. Retnakaran R, Hanley AJ, Raif N, Hirning CR, et al. Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications. Diabetologia 2005;48:993-1001.
112. Retnakaran R, Hanley AJ, Raif N, Connelly PW, et al. Reduced adiponectin concentration in women with gestational diabetes: a potential factor in progression to type 2 diabetes. Diabetes Care 2004;27:799-800.
113. Thyfault JP, Hedberg EM, Anchan RM, Thorne OP, et al. Gestational diabetes is associated with depressed adiponectin levels. J Soc Gynecol Investig 2005;12:41-45.
114. Tsai PJ, Yu CH, Hsu SP, Lee YH, et al. Maternal plasma adiponectin concentrations at 24 to 31 weeks of gestation: negative association with gestational diabetes mellitus. Nutrition 2005;21:1095-1099.
115. Weerakiet S, Lertnarkorn K, Panburana P, Pitakitronakorn S, et al. Can adiponectin predict gestational diabetes? Gynecol Endocrinol 2006;22:362-368.
116. Williams MA, Qiu C, Muy-Rivera M, Vadachkoria S, et al. Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. J Clin Endocrinol Metab 2004;89:2306-2311.
117. Winzer C, Wagner O, Festa A, Schneider B, et al. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 2004;27:1721-1727.
118. Worda C, Leipold H, Gruber C, Kautzky-Willer A, et al. Decreased plasma adiponectin concentrations in women with gestational diabetes mellitus. Am J Obstet Gynecol 2004;191:2120-2124.
119. Katoh M, Katoh M. Human FOX gene family (Review). Int J Oncol 2004;25:1495-1500.
120. Cederberg A, Gronning LM, Ahren B, Tasken K, et al. FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance. Cell 2001;106:563-573.
121. Carlsson E, Groop L, Ridderstrale M. Role of the FOXC2-512C>T polymorphism in type 2 diabetes: possible association with the dysmetabolic syndrome. Int J Obes (Lond) 2005;29:268-274.
122. Fritsche A, Machicao F, Staiger H, Haring HU, et al. Lack of association between metabolic traits and the -512 polymorphism in FOXC2 in German people with normal glucose tolerance. Diabetologia 2004;47:756-757.
123. Yanagisawa K, Hingstrup LL, Andersen G, Drivsholm T, et al. The FOXC2-512C>T variant is associated with hypertriglyceridaemia and increased serum C-peptide in Danish Caucasian glucose-tolerant subjects. Diabetologia 2003;46:1576-1580.
124. Kovacs P, Lehn-Stefan A, Stumvoll M, Bogardus C, et al. Genetic variation in the human winged helix/forkhead transcription factor gene FOXC2 in Pima Indians. Diabetes 2003;52:1292-1295.
125. Osawa H, Onuma H, Murakami A, Ochi M, et al. Systematic search for single nucleotide polymorphisms in the FOXC2 gene: the absence of evidence for the association of three frequent single nucleotide polymorphisms and four common haplotypes with Japanese type 2 diabetes. Diabetes 2003;52:562-567.
126. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971-980.
127. Vaxillaire M, Froguel P. Genetic basis of maturity-onset diabetes of the young. Endocrinol Metab Clin North Am 2006;35:371-84, x.
128. Bonnycastle LL, Willer CJ, Conneely KN, Jackson AU, et al. Common variants in maturity-onset diabetes of the young genes contribute to risk of type 2 diabetes in Finns. Diabetes 2006;55:2534-2540.
129. Shaat N, Karlsson E, Lernmark A, Ivarsson S, et al. Common variants in MODY genes increase the risk of gestational diabetes mellitus. Diabetologia 2006;49:1545-1551.
130. Allan CJ, Argyropoulos G, Bowker M, Zhu J, et al. Gestational diabetes mellitus and gene mutations which affect insulin secretion. Diabetes Res Clin Pract 1997;36:135-141.
131. Chiu KC, Go RC, Aoki M, Riggs AC, et al. Glucokinase gene in gestational diabetes mellitus: population association study and molecular scanning. Diabetologia 1994;37:104-110.
132. Lauenborg J, Damm P, Ek J, Glumer C, et al. Studies of the Ala/Val98 polymorphism of the hepatocyte nuclear factor-1alpha gene and the relationship to beta-cell function during an OGTT in glucose-tolerant women with and without previous gestational diabetes mellitus. Diabet Med 2004;21:1310-1315.
133. Zurawek M, Wender-Ozegowska E, Januszkiewicz-Lewandowska D, Zawiejska A, et al. GCK and HNF1alpha mutations and polymorphisms in Polish women with gestational diabetes. Diabetes Res Clin Pract 2007;76:157-158.
134. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000;343:338-344.
135. Soell M, Lett E, Holveck F, Scholler M, et al. Activation of human monocytes by streptococcal rhamnose glucose polymers is mediated by CD14 antigen, and mannan binding protein inhibits TNF-alpha release. J Immunol 1995;154:851-860.
136. Kilpatrick DC. Mannan-binding lectin: clinical significance and applications. Biochim Biophys Acta 2002;1572:401-413.
137. Garred P, Thiel S, Madsen HO, Ryder LP, et al. Gene frequency and partial protein characterization of an allelic variant of mannan binding protein associated with low serum concentrations. Clin Exp Immunol 1992;90:517-521.
138. Madsen HO, Garred P, Thiel S, Kurtzhals JA, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995;155:3013-3020.
139. Sumiya M, Super M, Tabona P, Levinsky RJ, et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991;337:1569-1570.
140. Hansen TK, Tarnow L, Thiel S, Steffensen R, et al. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004;53:1570-1576.
141. Megia A, Gallart L, Fernandez-Real JM, Vendrell J, et al. Mannose-binding lectin gene polymorphisms are associated with gestational diabetes mellitus. J Clin Endocrinol Metab 2004;89:5081-5087.
142. Saido TC, Sorimachi H, Suzuki K. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 1994;8:814-822.
143. Patel YM, Lane MD. Role of calpain in adipocyte differentiation. Proc Natl Acad Sci U S A 1999;96:1279-1284.
144. Smith LK, Rice KM, Garner CW. The insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes is mediated by a calcium-dependent thiol protease. Mol Cell Endocrinol 1996;122:81-92.
145. Horikawa Y, Oda N, Cox NJ, Li X, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000;26:163-175.
146. Weedon MN, Schwarz PE, Horikawa Y, Iwasaki N, et al. Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am J Hum Genet 2003;73:1208-1212.
147. Leipold H, Knofler M, Gruber C, Haslinger P, et al. Calpain-10 haplotype combination and association with gestational diabetes mellitus. Obstet Gynecol 2004;103:1235-1240.
148. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 2005;25:2043-2053.
149. Correia ML, Haynes WG. A role for plasminogen activator inhibitor-1 in obesity: from pie to PAI? Arterioscler Thromb Vasc Biol 2006;26:2183-2185.
150. Alessi MC, Bastelica D, Morange P, Berthet B, et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000;49:1374-1380.
151. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131-1137.
152. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-1855.
153. Berberoglu M, Evliyaoglu O, Adiyaman P, Ocal G, et al. Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children. J Pediatr Endocrinol Metab 2006;19:741-748.
154. Bouchard L, Mauriege P, Vohl MC, Bouchard C, et al. Plasminogen-activator inhibitor-1 polymorphisms are associated with obesity and fat distribution in the Quebec Family Study: evidence of interactions with menopause. Menopause 2005;12:136-143.
155. Leipold H, Knoefler M, Gruber C, Klein K, et al. Plasminogen activator inhibitor 1 gene polymorphism and gestational diabetes mellitus. Obstet Gynecol 2006;107:651-656.
156. Li LS, Lonnqvist F, Luthman H, Arner P. Phenotypic characterization of the Trp64Arg polymorphism in the beta 3-adrenergic receptor gene in normal weight and obese subjects. Diabetologia 1996;39:857-860.
157. Stone LM, Kahn SE, Fujimoto WY, Deeb SS, et al. Avariation at position -30 of the beta-cell glucokinase gene promoter is associated with reduced beta-cell function in middle-aged Japanese-American men. Diabetes 1996;45:422-428.